{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:40:46Z","timestamp":1792816846959,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000948","name":"Pfizer Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.ijantimicag.2019.01.002","type":"journal-article","created":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T17:23:45Z","timestamp":1547141025000},"page":"589-597","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"title":["Contemporary management and clinical outcomes of mucormycosis: A systematic review and meta-analysis of case reports"],"prefix":"10.1016","volume":"53","author":[{"given":"Wirawan","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Keighley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Leng","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica A.","family":"Slavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon C-A.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.M.","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0001","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1128\/CMR.18.3.556-569.2005","article-title":"Novel perspectives on mucormycosis: pathophysiology, presentation, and management","volume":"18","author":"Spellberg","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0002","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1128\/AAC.00452-07","article-title":"In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents","volume":"51","author":"Almyroudis","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0003","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jac\/dkg020","article-title":"In vitro susceptibilities of zygomycetes to conventional and new antifungals","volume":"51","author":"Dannaoui","year":"2003","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"Suppl 5","key":"10.1016\/j.ijantimicag.2019.01.002_bib0004","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1469-0691.2009.02984.x","article-title":"In vitro activity of antifungals against zygomycetes","volume":"15","author":"Alastruey-Izquierdo","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0005","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/imj.12598","article-title":"Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014","volume":"44","author":"Blyth","year":"2014","journal-title":"Intern Med J"},{"issue":"Suppl 3","key":"10.1016\/j.ijantimicag.2019.01.002_bib0006","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1469-0691.12371","article-title":"ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013","volume":"20","author":"Cornely","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0007","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0008","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3324\/haematol.2012.065110","article-title":"Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3)","volume":"98","author":"Skiada","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0009","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case\u2013control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0010","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/jac\/dkr375","article-title":"The Deferasirox\u2013AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial","volume":"67","author":"Spellberg","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0011","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1093\/jac\/dkv236","article-title":"Prospective pilot study of high-dose (10 mg\/kg\/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis","volume":"70","author":"Lanternier","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0012","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: a review of 929 reported cases","volume":"41","author":"Roden","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0013","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0014","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0015","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cmi.2016.01.005","article-title":"Mucormycosis in Australia: contemporary epidemiology and outcomes","volume":"22","author":"Kennedy","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0016","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1017\/S0266462312000086","article-title":"The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies","volume":"28","author":"Morrison","year":"2012","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0017","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cmi.2018.07.011","article-title":"The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports","volume":"25","author":"Jeong","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0018","doi-asserted-by":"crossref","first-page":"7224","DOI":"10.1128\/AAC.01698-15","article-title":"Toxicity of amphotericin B deoxycholate-based induction therapy in patients with HIV-associated cryptococcal meningitis","volume":"59","author":"Bicanic","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0019","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/jphp.12802","article-title":"Efficacy and safety of amphotericin B formulations: a network meta-analysis and a multicriteria decision analysis","volume":"69","author":"Tonin","year":"2017","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0020","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1128\/AAC.45.12.3487-3496.2001","article-title":"Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study","volume":"45","author":"Walsh","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0021","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1093\/jac\/dkw322","article-title":"Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and\/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience","volume":"71","author":"Jeong","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0022","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1128\/AAC.00157-06","article-title":"Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients","volume":"50","author":"Gubbins","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0023","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1128\/AAC.04435-14","article-title":"Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales","volume":"59","author":"Espinel-Ingroff","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179136","article-title":"Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: epidemiology and microbiological characterization of the isolates","volume":"12","author":"Guinea","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0025","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ijantimicag.2016.07.005","article-title":"Antifungal susceptibilities of non-Aspergillus filamentous fungi causing invasive infection in Australia: support for current antifungal guideline recommendations","volume":"48","author":"Halliday","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0026","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/jac\/dkx440","article-title":"Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: factors affecting trough plasma concentrations","volume":"73","author":"Jeong","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0027","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1128\/AAC.00973-15","article-title":"Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA\u2013itraconazole and Sporanox capsule formulations in healthy subjects in fed and fasted states","volume":"59","author":"Abuhelwa","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0028","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1128\/AAC.01458-07","article-title":"Combination echinocandin\u2013polyene treatment of murine mucormycosis","volume":"52","author":"Ibrahim","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0029","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1086\/589857","article-title":"Combination polyene\u2013caspofungin treatment of rhino-orbital-cerebral mucormycosis","volume":"47","author":"Reed","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2016.03.029","article-title":"Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis","volume":"22","author":"Kyvernitakis","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0031","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1128\/AAC.01124-08","article-title":"Posaconazole mono- or combination therapy for treatment of murine zygomycosis","volume":"53","author":"Ibrahim","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0032","first-page":"673","article-title":"Combined effects of hyperbaric oxygen and antifungal agents on the growth of Candida albicans","volume":"58","author":"Gudewicz","year":"1987","journal-title":"Aviat Space Environ Med"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0033","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/00006534-199701000-00023","article-title":"Ischemic tissue oxygen capacitance after hyperbaric oxygen therapy: a new physiologic concept","volume":"99","author":"Siddiqui","year":"1997","journal-title":"Plast Reconstr Surg"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2019.01.002_bib0034","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1093\/cid\/cir880","article-title":"A global analysis of mucormycosis in France: The RetroZygo study (2005\u20132007)","volume":"54","author":"Lanternier","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0035","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/j.1469-0691.2010.03456.x","article-title":"Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007","volume":"17","author":"Skiada","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0036","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1182\/blood-2011-03-316430","article-title":"How I treat mucormycosis","volume":"118","author":"Kontoyiannis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0037","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/590004","article-title":"Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis","volume":"47","author":"Chamilos","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0038","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3109\/13693786.2012.690107","article-title":"Increased virulence of Cunninghamella bertholletiae in experimental pulmonary mucormycosis: correlation with circulating molecular biomarkers, sporangiospore germination and hyphal metabolism","volume":"51","author":"Petraitis","year":"2013","journal-title":"Med Mycol"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0039","doi-asserted-by":"crossref","first-page":"7882","DOI":"10.1128\/AAC.02107-15","article-title":"Comparison of the EUCAST and CLSI broth microdilution methods for testing isavuconazole, posaconazole, and amphotericin B against molecularly identified Mucorales species","volume":"59","author":"Chowdhary","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.002_bib0040","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/1756-0500-7-264","article-title":"The clinical case report: a review of its merits and limitations","volume":"7","author":"Nissen","year":"2014","journal-title":"BMC Res Notes"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919300020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919300020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:32:26Z","timestamp":1760376746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857919300020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0924857919300020"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.01.002","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary management and clinical outcomes of mucormycosis: A systematic review and meta-analysis of case reports","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}